

# Signaling Pathways That Drive $^{18}\text{F}$ -FDG Accumulation in Cancer

Jessica R. Salas and Peter M. Clark

*Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California*

$^{18}\text{F}$ -FDG measures glucose consumption and is an integral part of cancer management. Most cancer types upregulate their glucose consumption, yielding elevated  $^{18}\text{F}$ -FDG PET accumulation in those cancer cells. The biochemical pathway through which  $^{18}\text{F}$ -FDG accumulates in cancer cells is well established. However, beyond well-known regulators such as c-Myc, PI3K/PKB, and HIF1 $\alpha$ , the proteins and signaling pathways that cancer cells modulate to activate the facilitated glucose transporters and hexokinase enzymes that drive elevated  $^{18}\text{F}$ -FDG accumulation are less well understood. Understanding these signaling pathways could yield additional biologic insights from  $^{18}\text{F}$ -FDG PET scans and could suggest new uses of  $^{18}\text{F}$ -FDG PET in the management of cancer. Work over the past 5 years, building on studies from years prior, has identified new proteins and signaling pathways that drive glucose consumption in cancer. Here, we review these recent studies and discuss current limitations to our understanding of glucose consumption in cancer.

**Key Words:** molecular imaging; oncology;  $^{18}\text{F}$ -FDG PET; cancer; glucose consumption; signaling pathways

**J Nucl Med 2022; 63:659–663**  
DOI: 10.2967/jnumed.121.262609

The glucose analog PET radiotracer  $^{18}\text{F}$ -FDG measures glucose consumption and is an important tool for the diagnosis and management of cancer (1,2).  $^{18}\text{F}$ -FDG PET imaging has demonstrated value in, for example, the initial staging and the identification of recurrences in lung, colorectal, and esophageal cancers (1). Additionally, preclinical and clinical studies suggest that changes in  $^{18}\text{F}$ -FDG accumulation in tumors after certain therapies can be strongly predictive and can function as an early biomarker of therapeutic efficacy (3,4).

However, despite the proven clinical value of  $^{18}\text{F}$ -FDG PET in cancer management and a clear understanding of the biochemical pathway that  $^{18}\text{F}$ -FDG measures—glucose consumption—a comprehensive understanding of the signaling pathways that regulate glucose consumption and  $^{18}\text{F}$ -FDG accumulation in cancer is lacking. Understanding these signaling pathways could provide a better context in which to understand  $^{18}\text{F}$ -FDG PET scans in patients, might help to connect mechanistically the level of  $^{18}\text{F}$ -FDG accumulation to specific and potentially targetable alterations in a given cancer type, and might aid in identifying additional therapies for which  $^{18}\text{F}$ -FDG PET could be leveraged as an early predictor of therapeutic efficacy.

This review describes and categorizes new signaling pathways that regulate glucose consumption in cancer and that have been reported within the last 5 years. Most of these newly described pathways connect to well-established and previously identified regulators of cancer cell glucose consumption such as PI3K, HIF1 $\alpha$ , and TXNIP. Work describing these and other previously identified regulators of glucose consumption can be found in prior reviews (5–8). Mechanisms through which therapies block  $^{18}\text{F}$ -FDG accumulation and glucose consumption in cancer are important although beyond the scope of this review. Additionally, mechanisms that drive  $^{18}\text{F}$ -FDG accumulation in immune cells in the tumor microenvironment and how that information could be used to monitor therapeutic responses to immune checkpoint inhibitors are an important additional topic but also outside the scope of this review and at least partially covered by a recent review (9).

## THE BIOCHEMISTRY OF $^{18}\text{F}$ -FDG ACCUMULATION

$^{18}\text{F}$ -FDG is transported across the cell membrane by facilitated glucose transporters (GLUTs) and is phosphorylated by hexokinase enzymes to  $^{18}\text{F}$ -FDG-6-phosphate (2). The GLUTs are a large family of transporters containing 14 isoforms that transport glucose and related compounds (10). GLUT1 and GLUT3 both transport glucose and  $^{18}\text{F}$ -FDG, are highly expressed in a variety of cancers, and are considered the key transporters of  $^{18}\text{F}$ -FDG in most cancer cells (10,11).  $^{18}\text{F}$ -FDG is not a substrate for sodium-dependent glucose transporters (12), although the exact contribution of these transporters to glucose flux in cancer remains to be determined. Cells express one or more of 4 different hexokinases (13). Hexokinase 1 (HK1) and hexokinase 2 (HK2), alone or in combination, are expressed in most cancer cells and are considered the key enzymes for phosphorylating  $^{18}\text{F}$ -FDG to  $^{18}\text{F}$ -FDG-6-phosphate in cancer cells (13).  $^{18}\text{F}$ -FDG-6-phosphate can be dephosphorylated by glucose-6-phosphatase and transported out of the cell by the GLUTs (14).

Which of these biochemical steps is the major driver of  $^{18}\text{F}$ -FDG accumulation is likely context-dependent, and low levels of the GLUTs or hexokinase enzymes or high levels of glucose-6-phosphatase are often found in cancers that accumulate low levels of  $^{18}\text{F}$ -FDG. For example, in non-small cell lung cancer, GLUT1 and GLUT3 levels correlate better than HK1 and HK2 levels with  $^{18}\text{F}$ -FDG accumulation (15). In pheochromocytomas and paragangliomas, HK2 levels correlate better than GLUT1 or GLUT3 levels with  $^{18}\text{F}$ -FDG accumulation (16).  $^{18}\text{F}$ -FDG accumulation can be variable in gastric and breast cancers, and in both cases,  $^{18}\text{F}$ -FDG accumulation correlates with GLUT1 levels (17,18). Low  $^{18}\text{F}$ -FDG accumulation in low-grade hepatocellular carcinoma tumors is associated with low hexokinase activity and high glucose-6-phosphatase activity (19).

Received Dec. 21, 2021; revision accepted Feb. 22, 2022.  
For correspondence or reprints, contact Peter M. Clark (pclark@mednet.ucla.edu).  
Guest Editor: Carolyn Anderson, University of Missouri  
Published online Mar. 3, 2022.  
COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Additional enzymes, including phosphoglucose isomerase and phosphoglucosylase, can further metabolize  $^{18}\text{F}$ -FDG-6-phosphate (20), but how (if at all) changes in the activity of these enzymes affects  $^{18}\text{F}$ -FDG accumulation at the time point usually used for imaging with  $^{18}\text{F}$ -FDG remains unclear.

### THE SIGNALING PATHWAYS THAT AFFECT GLUCOSE CONSUMPTION AND $^{18}\text{F}$ -FDG ACCUMULATION IN CANCER CELLS

Many well-validated methods exist for quantifying glucose consumption, including measuring 2-DG-6-phosphate levels in cells treated with 2-DG, measuring accumulated radioactivity in cells treated with a radiolabeled glucose analog, or measuring changes in glucose concentrations in cell culture media (21). An often-used but poor measure of glucose consumption is accumulated fluorescence in cells treated with a fluorescent glucose analog such as 2-[*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose or 6-[*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose. Various studies have identified multiple systems in which the accumulation of these fluorescent glucose analogs does not measure glucose consumption (22,23). As such, we will focus only on those studies that measure glucose consumption with well-validated methods.

Over the last 5 years, most studies have identified signaling pathways that regulate glucose consumption and  $^{18}\text{F}$ -FDG accumulation by regulating the GLUT proteins and hexokinase enzymes at the transcriptional and posttranslational level.

#### TRANSCRIPTION (FIG. 1A)

Newly identified regulators of GLUT1 and GLUT3 transcription are varied and defy easy categorization. In squamous cell carcinoma cell lines, the transcription factors p63 and SOX2 drive glucose consumption by binding to an enhancer region of the GLUT1 gene and driving GLUT1 messenger RNA (mRNA) and protein expression (24). Our laboratory recently identified over 100 small molecules that block glucose consumption in 1 of 3 different non-small cell lung cancer cell lines using a high-throughput assay. We studied the small molecule miliciclib and used it to determine that the cyclin-dependent kinase CDK7 activates GLUT1 transcription, glucose consumption, and  $^{18}\text{F}$ -FDG accumulation downstream from mutant PIK3CA (25). In melanoma cells, lysine methyl transferase KMT2D loss-of-function mutants increase glucose consumption by repressing the expression of IGFBP5, a negative regulator of insulin signaling, and increase mRNA expression of GLUT1 and HK1 (26). In pre-B-cell acute lymphoblastic leukemia, B-lymphoid transcription factors Pax5 and IKZF1 function as tumor suppressors and downregulate mRNA levels of GLUT1 and HK2 (27). In breast and colorectal cancer cells, during cell detachment, the protein kinase SGK1 induces the expression of GLUT1 mRNA, leading to increased GLUT1 protein levels and glucose consumption (28). In pancreatic cancer, the transmembrane mucin glycoprotein MUC13 increases glucose consumption by activating nuclear factor  $\kappa\text{B}$ , leading to increased mRNA expression of GLUT1 (29). Finally, in cervical cancer cells, long noncoding RNA NIC1 enhances glucose consumption during hypoxia by promoting the recruitment of RNA polymerase 2 to the GLUT3 promoter and increasing GLUT3 mRNA levels (30).

The transcription factor c-Myc continues to be an important regulator of glucose consumption, with attention in the last 5 years focusing on its role in regulating HK2 mRNA levels. In colon cancer cells, interleukin 22 enhances glucose consumption by activating STAT3, which

induces c-Myc mRNA and protein levels, leading to increased mRNA and protein expression of HK2 (31). Alternatively, in pancreatic cancer cells, serotonin activates glucose consumption in cells by binding its receptor HTR2B, increasing protein levels of HIF1 $\alpha$  and c-Myc, and increasing mRNA expression of HK2 (32). Inhibition of mTOR and c-Myc in lymphoma cell lines decreases glucose consumption, decreases mRNA levels of GLUT1, and increases mRNA levels of glucose-6-phosphatase (33).

Additional regulators of HK2 transcription include the transcription factor BACH1, the cytokine Gremlin-1, and the micro RNA miR-34c-3p. In lung cancer cells, BACH1, which is stabilized in the presence of antioxidants, binds to the HK2 promoter and induces HK2 mRNA levels, leading to increased glucose consumption (34). In breast cancer cells, Gremlin-1 induces glucose consumption by activating the reactive oxygen species–PKB (Akt)–STAT3 pathway, which leads to increased HK2 mRNA (35). Finally, in hepatocellular carcinoma cell lines, miR-34c-3p drives glucose consumption by downregulating guanylate kinase MAGI3. MAGI3 inhibits  $\beta$ -catenin transcriptional activity, and decreased MAGI3 levels leads to increased HK2 mRNA levels and glucose consumption (36).

#### PROTEIN EXPRESSION (FIG. 1B)

A few studies only looked at protein levels of GLUT1 and HK2. In osteosarcoma cells, the long noncoding RNA MALAT1 sponges up miR-485-3p, leading to higher levels of c-MET and Akt3, whose mRNA miR-485-3p targets. Higher c-MET and Akt3 protein levels increase mTOR signaling, GLUT1 and HK2 protein levels, and glucose consumption (37). In cervical cancer cells, programmed-death ligand 1 activates glucose consumption through the induction of SNAI1, which represses SIRT3 expression, leading to higher protein levels of HK2 and GLUT1 (38).

#### POSTTRANSLATIONAL REGULATION AND LOCALIZATION (FIG. 1C)

Recent work has focused on the posttranslational modifications of HK2 (39,40). SUMOylation and ubiquitination represent the conjugation of specific polypeptides to lysine residues on proteins. HK2 SUMOylation at lysine 315 and lysine 492 is added by the conjugating enzyme UBC2 and removed by the protease SENP1. In prostate cancer cells, HK2 SUMOylation weakens the interaction between HK2 and the anion channel VDAC on the outer mitochondrial membrane, leading to lower glucose consumption (39). In hepatocellular carcinoma, the COP9 signalosome subunit CSN5 is overexpressed and deubiquitinates HK2. HK2 ubiquitination is associated with its degradation, so CSN5 overexpression leads to increased HK2 protein levels and glucose consumption (40).


The  $\alpha$ -arrestin family member TXNIP is a well-studied protein whose levels are induced by glucose, which binds to GLUT1, leading to GLUT1 internalization, and which decreases GLUT1 mRNA levels (41). In this capacity, TXNIP is a key effector of a negative-feedback loop that limits excess glucose consumption and a key node that is dysregulated in cancer cells to enhance glucose consumption (41). In recent work, the role of TXNIP in regulating glucose consumption continued to be affirmed, with studies identifying additional regulators of TXNIP levels (42–45).

Lower TXNIP levels lead to increased GLUT1 at the plasma membrane and increased glucose consumption (42). PI3K/Akt signaling in non-small cell lung cancer cell lines decreases TXNIP expression and increases glucose consumption. In a hepatocellular carcinoma cell line, growth factors induce rapid glucose uptake by activating

PI3K/Akt signaling, leading to the phosphorylation of TXNIP and yielding a weaker interaction between TXNIP and GLUT1 (43,44). Across a variety of cancer cell lines, reducing hyaluronan levels activates receptor tyrosine kinase signaling, leading to induction of the zinc finger protein ZNF36, which degrades TXNIP mRNA (42). ZNF36 also binds to and contributes to the degradation of HK2 mRNA (46), suggesting that ZNF36 may regulate glucose consumption through multiple mechanisms. In metastatic pancreatic cancer cells, elevated activity of the metabolic enzyme phosphogluconate dehydrogenase increases glucose consumption by depleting levels of its substrate, 6-phosphogluconate, leading to retention of the transcription factor MondoA in the cytoplasm and diminished expression

of the Mondo target gene TXNIP. Lower TXNIP levels lead to increased GLUT1 surface expression (45). In pancreatic cancer cells, the cell-surface glycoprotein MUC13 also directly interacts with and stabilizes GLUT1 at the cell surface, potentially synergizing with decreased levels of TXNIP (29).

The GTPase KRAS is highly mutated and activated in many different types of cancer and is well known to activate glucose consumption (47). However, mechanisms for how KRAS activates glucose consumption are not fully understood. KRAS is expressed as 2 splice variants, KRAS4A and KRAS4B. Recent work has shown that in multiple cancer cell lines, KRAS4A directly interacts with HK1 at the outer mitochondrial membrane, where it relieves



**FIGURE 1.** Recently described regulators of GLUT and hexokinase transcription (A), expression (B), and posttranslational regulation and localization (C).

glucose-6-phosphate-dependent product inhibition of HK1, leading to increased glucose consumption (48).

### LIMITATIONS TO OUR CURRENT UNDERSTANDING OF GLUCOSE CONSUMPTION IN CANCER CELLS

Most proteins identified to regulate cancer cell glucose consumption have been shown to do so only in established cancer cell lines and in cell cultures despite the fact that metabolism can be very different between cell cultures and in vivo. Small-animal  $^{18}\text{F}$ -FDG PET is an ideal and well-established assay for conducting such studies but is rarely used. Additional studies to evaluate regulators of glucose consumption in vivo are necessary. Ideally, these studies would be done using patient-derived xenografts implanted in orthotopic locations or genetically engineered mouse models.

Most proteins that have been shown to alter glucose consumption have been studied in one or a limited number of cell lines from the same cancer type. The activity of these proteins is often not linked to any known genetic alteration. Studies evaluating which signaling pathways are cancer-type-specific or are shared across different cancer types will be important for identifying the scope of any pathway identified. Studies determining the genetic or epigenetic alteration that activates a certain pathway to drive glucose consumption will serve the same purpose.

The data so far suggest that glucose consumption is regulated at multiple levels by various mechanisms. Largely understudied is the relative importance of each regulator in affecting glucose consumption. Proteins or pathways that drive a large proportion of the glucose consumption would likely have greater relevance for human  $^{18}\text{F}$ -FDG PET.

An emerging but understudied theme is that blocking glucose consumption by affecting the identified pathways limits cell growth. For example, we have shown that the cyclin-dependent kinase inhibitor miliciclib blocks cell growth by inhibiting glucose consumption (25). If this proves to be true across many different therapies and cancer types, it would provide a causal basis for correlative clinical studies showing that early changes in tumor  $^{18}\text{F}$ -FDG accumulation in response to therapy can be predictive of therapeutic efficacy.

To identify additional drugs for which  $^{18}\text{F}$ -FDG could function as a pharmacodynamic biomarker, it will be important to understand the kinetic time course over which glucose consumption is affected after a drug treatment. For example, because EGFR inhibitors block glucose consumption in glioblastoma cells within 4 h and through 24 h (4), a patient could be imaged with  $^{18}\text{F}$ -FDG PET shortly after or up through a day after administration of an EGFR inhibitor. Miliciclib affects glucose consumption only after 24 h (25); a patient would therefore need to be imaged with  $^{18}\text{F}$ -FDG PET 24 h after miliciclib treatment. Earlier imaging of a patient treated with miliciclib could lead to the false impression that miliciclib was not working in the tumor.

Tumors contain a complex mixture of cells, including cancer cells, immune cells, and stromal cells. The amount of glucose consumption in these various cell types and how that relates to the overall accumulation of  $^{18}\text{F}$ -FDG in the tumor across different cancer types and locations remains to be fully determined. However, a recent study suggested that at least in certain tumor models, myeloid cells and T cells consume glucose at a higher rate than tumor cells (49). Further studies will be necessary to understand how much  $^{18}\text{F}$ -FDG accumulation in tumors represents  $^{18}\text{F}$ -FDG accumulation in cancer cells versus other cell types.

### CONCLUSION

$^{18}\text{F}$ -FDG PET is an established imaging approach for the management of many different types of cancer, but the full repertoire of signaling pathways that drive  $^{18}\text{F}$ -FDG consumption in cancer are not well understood. A better understanding of these signaling pathways could yield new insights into  $^{18}\text{F}$ -FDG PET imaging and will be important for developing additional uses of  $^{18}\text{F}$ -FDG PET in cancer.

Critical and important work has been accomplished over the last 5 years to further elucidate the detailed mechanisms that cancer cells use to elevate their glucose consumption and that lead to increased  $^{18}\text{F}$ -FDG accumulation in cancer cells. These studies continue to support the role of well-studied primary regulators of glucose consumption, including PI3K/Akt, mTOR, and HIF1 $\alpha$ , while detailing the different ways in which these primary regulators control glucose consumption at the transcriptional and post-translational level. Studies in the next 5 years should focus on how and whether the regulators of glucose consumption often identified in limited cell lines and in cell cultures translate in vivo to mice and potentially humans and across various types and subtypes of cancer.

### DISCLOSURE

No potential conflict of interest relevant to this article was reported.

### REFERENCES

1. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. *Radiographics*. 2003;23:315–340.
2. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. *Proc Natl Acad Sci USA*. 2000;97:9226–9233.
3. de Geus-Oei L-F, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG. Monitoring and predicting response to therapy with  $^{18}\text{F}$ -FDG PET in colorectal cancer: a systematic review. *J Nucl Med*. 2009;50(suppl 1):43S–54S.
4. Mai WX, Gosa L, Daniels VW, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. *Nat Med*. 2017;23:1342–1351.
5. Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. *Jpn Dent Sci Rev*. 2018;54:8–21.
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab*. 2008;7:11–20.
7. Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? *Nat Rev Cancer*. 2016;16:635–649.
8. Zhao M, Zhang Z. Glucose transporter regulation in cancer: a profile and the loops. *Crit Rev Eukaryot Gene Expr*. 2016;26:223–238.
9. Irvani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacologic intervention, part 1: the role of  $^{18}\text{F}$ -FDG PET/CT. *J Nucl Med*. 2020;61:943–950.
10. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. *Curr Opin Oncol*. 2012;24:650–654.
11. Jadvar H, Alavi A, Gambhir SS.  $^{18}\text{F}$ -FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. *J Nucl Med*. 2009;50:1820–1827.
12. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. *Physiol Rev*. 2011;91:733–794.
13. Xu S, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-null/hexokinase 2-positive cancers. *Cancer Res*. 2019;79:5907–5914.
14. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. *Ann Neurol*. 1979;6:371–388.
15. de Geus-Oei L-F, van Krieken JHJM, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. *Lung Cancer*. 2007;55:79–87.

16. van Berkel A, Rao JU, Kusters B, et al. Correlation between in vivo <sup>18</sup>F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. *J Nucl Med.* 2014;55:1253–1259.
17. Alakus H, Batur M, Schmidt M, et al. Variable <sup>18</sup>F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. *Nucl Med Commun.* 2010;31:532–538.
18. Bos R, van Der Hoeven JJM, van Der Wall E, et al. Biologic correlates of <sup>18</sup>fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. *J Clin Oncol.* 2002;20:379–387.
19. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. *J Nucl Med.* 1995;36:1811–1817.
20. Southworth R, Parry CR, Parkes HG, Medina RA, Garlick PB. Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: a <sup>19</sup>F NMR spectroscopy study in the rat. *NMR Biomed.* 2003;16:494–502.
21. TeSlaa T, Teitell MA. Techniques to monitor glycolysis. *Methods Enzymol.* 2014;542:91–114.
22. Sinclair LV, Barthelemy C, Cantrell DA. Single cell glucose uptake assays: a cautionary tale. *Immunometabolism.* 2020;2:e200029.
23. Hamilton KE, Bouwer MF, Louters LL, Looyenga BD. Cellular binding and uptake of fluorescent glucose analogs 2-NBDG and 6-NBDG occurs independent of membrane glucose transporters. *Biochimie.* 2021;190:1–11.
24. Hsieh M-H, Choe JH, Gadhvi J, et al. p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas. *Cell Rep.* 2019;28:1860–1878.e9.
25. Ghezzi C, Wong A, Chen BY, Ribalet B, Damoiseaux R, Clark PM. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. *Nat Commun.* 2019;10:5444.
26. Maitiuheti M, Keung EZ, Tang M, et al. Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma. *Cell Rep.* 2020;33:108293.
27. Chan LN, Chen Z, Braas D, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. *Nature.* 2017;542:479–483.
28. Mason JA, Cockfield JA, Pape DJ, et al. SGK1 signaling promotes glucose metabolism and survival in extracellular matrix detached cells. *Cell Rep.* 2021;34:108821.
29. Kumari S, Khan S, Gupta SC, et al. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. *Oncogenesis.* 2018;7:19.
30. Lauer V, Grampp S, Platt J, et al. Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)-mediated induction of the long noncoding RNA NIC1. *J Biol Chem.* 2020;295:4065–4078.
31. Liu Y, Xiang F, Huang Y, et al. Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells. *Oncotarget.* 2017;8:25372–25383.
32. Jiang S-H, Li J, Dong F-Y, et al. Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. *Gastroenterology.* 2017;153:277–291.e19.
33. Broecker-Preuss M, Becher-Boveleth N, Bockisch A, Dührsen U, Müller S. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability. *J Transl Med.* 2017;15:158.
34. Wiel C, Le Gal K, Ibrahim MX, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. *Cell.* 2019;178:330–345.e22.
35. Kim NH, Sung NJ, Youn H-S, Park S-A. Gremlin-1 activates Akt/STAT3 signaling, which increases the glycolysis rate in breast cancer cells. *Biochem Biophys Res Commun.* 2020;533:1378–1384.
36. Weng Q, Chen M, Yang W, et al. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma. *FASEB J.* 2020;34:5420–5434.
37. Wang Q, Liu M-J, Bu J, et al. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. *Life Sci.* 2021;268:118925.
38. Wang S, Li J, Xie J, et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway. *Oncogene.* 2018;37:4164–4180.
39. Shanguan X, He J, Ma Z, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. *Nat Commun.* 2021;12:1812.
40. Huang M, Xiong H, Luo D, Xu B, Liu H. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein. *Exp Cell Res.* 2020;388:111876.
41. Wu N, Zheng B, Shaywitz A, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. *Mol Cell.* 2013;49:1167–1175.
42. Sullivan WJ, Mullen PJ, Schmid EW, et al. Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization. *Cell.* 2018;175:117–132.e21.
43. Hong SY, Yu F-X, Luo Y, Hagen T. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. *Cell Signal.* 2016;28:377–383.
44. Waldhart AN, Dykstra H, Peck AS, et al. Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. *Cell Rep.* 2017;19:2005–2013.
45. Bechard ME, Smalling R, Hayashi A, et al. Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis. *Nat Commun.* 2020;11:4055.
46. Kim DJ, Vo M-T, Choi SH, et al. Tristetraprolin-mediated hexokinase 2 expression regulation contributes to glycolysis in cancer cells. *Mol Biol Cell.* 2019;30:542–553.
47. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell.* 2012;149:656–670.
48. Amendola CR, Mahaffey JP, Parker SJ, et al. KRAS4A directly regulates hexokinase I. *Nature.* 2019;576:482–486.
49. Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. *Nature.* 2021;593:282–288.